key: cord-0994566-z7khs9rw
authors: Bruno, Giuseppe; Fabrizio, Claudia; Santoro, Carmen Rita; Buccoliero, Giovanni Battista
title: Pancreatic injury in the course of coronavirus disease 2019 (COVID‐19): a not‐so‐rare occurrence
date: 2020-06-04
journal: J Med Virol
DOI: 10.1002/jmv.26134
sha: ce2b3a972ea28386b5085ceecd90eb3b43488ba1
doc_id: 994566
cord_uid: z7khs9rw

Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID‐19), gastrointestinal manifestations are increasingly described. However, data regarding COVID‐19‐associated pancreatic injury are still limited, as well as the mechanisms underlying COVID‐19 induced‐pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID‐19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS‐CoV‐2, inflammatory cascade, dehydration and multiple organ dysfunction. This article is protected by copyright. All rights reserved.

pancreatic injury without clinical signs of severe pancreatitis (3) . Meanwhile, Hadi et al. reported severe acute pancreatitis in two first-line relatives in course of COVID-19 (4) .

So far, the mechanisms underlying COVID-19 induced-pancreatic damage have not been completely understood. It has been hypothesized that SARS-CoV-2 may use angiotensinconverting enzyme 2 (ACE2) receptors, highly expressed in pancreatic islet cells, to gain cellular entry thus resulting in a direct cytopathic effect (5).

On the other hand, pancreatic injury might depend on several indirect events including cytokine storm, immune response, as well as endothelial dysfunction, leading to a process called "viral sepsis", addressed to the multiple organ failure (MOF) (6).

Whether direct cytopathic effect may be mainly responsible for pancreatic injury, this represents a debated question deserving further investigations.

Considering this, among the 70 patients with documented COVID-19 hospitalised in our Infectious diseases unit from February 25, 2020 to May 10, 2020, six individuals (8.5%) showed pancreatic abnormalities (PA) without a history of alcohol abuse, gallstones, chronic biliary or pancreatic diseases and were included in this retrospective observational study. Clinical and biochemical data including serum amylase (normal range 10-100 U/L) and lipase (normal range 73-393 U/L) were collected during the hospitalisation. Hyperlipasemia was defined as an elevated lipase level above the upper limit of normal (> 393 U/L). Clinical features are summarized in Table 1 Although elevated lipase levels have been associated with non-pancreatic etiologies, including gastritis/gastroparesis and enteritis/colitis (8), we hypothesized that pancreatic damage may be related with several factors including direct effect of SARS-CoV-2, inflammatory cascade, dehydration, multiple organ dysfunction. Moreover, several drugs have been rarely associated with pancreatic damage (9). In addition, hypertriglyceridaemia, an important risk factor for pancreatitis, has been associated with lopinavir/ritonavir (LPV/r) in HIV patients (10). In our group, one patient showed a slight hypertriglyceridaemia (311 mg/dl).

Therefore, it is of paramount importance to implement the knowledge of the COVID-19associated pancreatic injury as well as drug-induced toxicity should be also taken into account as additional risk factor for developing pancreatic damage. A strict monitoring of pancreatic parameters should be performed during the management of COVID-19. 

The management of coronavirus disease 2019 (COVID-19)

Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19

Pancreatic injury patterns in patients with COVID-19 pneumonia

Coronavirus Disease-19 (COVID-19) associated with severe acute

All authors declare no conflict of interest.

Contribution: We all contributed to writing and editing the manuscript.

pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. 5. Liu